Replimune Group Inc (NAS:REPL)
$ 7.9 0.79 (11.11%) Market Cap: 485.18 Mil Enterprise Value: 91.86 Mil PE Ratio: 0 PB Ratio: 1.17 GF Score: 30/100

Replimune Group Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 05:45PM GMT
Release Date Price: $25.49 (-1.28%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Okay. Let's get started. Welcome to the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan.

I am joined by my team, Priyanka Grover and Malcolm Kuno. Our next presenting company is Replimune, and presenting on behalf of the company, we have the CEO. Philip?

Philip Astley;Sparke
Replimune Group, Inc. - CEO & Director

Thanks, Anupam. Replimune. Replimune is the industry leader in tumor-directed oncolytic immunotherapy. We have 3 wholly owned programs, RP1, 2 and 3. RP1 data to date supports the emergence of a major skin cancer franchise.

We have 2 registrational studies ongoing. The first is in frontline cutaneous squamous cell carcinoma, where in a prior single-arm study, we showed a very impressive almost 1 in 2 complete response rate.

We have subsequently fully enrolled a 211-patient randomized controlled study of RP1 plus cemiplimab standard of care against

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot